Investor Hub

Here you can keep up to date with our share price, upcoming events and latest presentations. We invite you to sign up for our email alerts and welcome any questions you may have.

REPCF Market Data

Corporate Name RepliCel Life Sciences.
Exchange/Symbol OTCQB/REPCF
Exchange/Symbol TSXV/RP
Shares Issued & Outstanding 14,926,162
Shares Issued on a Fully Diluted Basis 15,410,162
Insider Ownership 32%
CUSIP # 76027P103
ISIN # CA 76027P1036
Fiscal Year End December 31
Date of Incorporation 1967
Incorporated British Columbia, Canada
Industry Life Sciences
Transfer Agent Computershare
Corporate Attorneys Clark Wilson LLP
Auditors BDO Canada LLP
News Releases
May 25, 2017
RepliCel CEO Provides Company Outlook
April 25, 2017
United States Patent Issued to RepliCel for its Novel Dermal Injection Technologies
April 4, 2017
Positive Results from RepliCel’s RCS-01 Phase I Skin Trial are the Company’s Most Compelling to Date
Investor Relations Contact:
Lee Buckler

Email: lee@replicel.com
Tel: 604.248.8730